Sarepta Therapeutics : SRPT

All Sarepta Therapeutics Articles

141 Articles

Jon C. Ogg | Sep 20, 2016 at 8:45 AM EDT

Top Analyst Upgrades and Downgrades: American Electric Power, Broadcom, Ford, GM, JD.com, Sarepta, Valeant Pharmaceuticals and More

The top analyst upgrades, downgrades and initiations seen on Tuesday morning include American Electric Power, Broadcom, Ford, General Motors, JD.com,…

Chris Lange | Sep 19, 2016 at 12:25 PM EDT

Sarepta Scores Big on Highly Contested FDA Approval

Sarepta Therapeutics cleared another hurdle related to its Duchenne muscular dystrophy treatment, and the stock practically doubled on Monday.

Jon C. Ogg | Sep 15, 2016 at 8:55 AM EDT

Top Analyst Upgrades and Downgrades: Apple, AT&T, Autodesk, Bluebird Bio, Monsanto, Sarepta and More

The top analyst upgrades, downgrades and initiations seen on Thursday morning include Apple, AT&T, Autodesk, Bluebird Bio, Monsanto and Sarepta…

Chris Lange | Sep 14, 2016 at 4:37 PM EDT

Why This FDA Departure Is Huge for Sarepta

Sarepta Therapeutics closed out Wednesday with its shares up over 25% following positive developments surrounding eteplirsen, its treatment of Duchenne…

Lee Jackson | Jun 21, 2016 at 8:35 AM EDT

4 Red-Hot Biotech Stocks With Over 100% Upside Potential

These four biotech companies not only have data that could prove to be huge, but they have been absolutely hammered…

Trey Thoelcke | Jun 11, 2016 at 9:20 AM EDT

3 Biotechs That Just Announced Successful Phase 2 Trials

Here are three biotechs that just recently announced successful Phase 2 trial data for drugs with very big addressable markets.

Jon C. Ogg | Jun 7, 2016 at 10:10 AM EDT

Why Analysts Are Still All Over the Place on Sarepta After FDA News

[cnxvideo id=”655243″ placement=”ros”]Sarepta Therapeutics Inc. (NASDAQ: SRPT) has seen more than its fair share of volatility in the market of…

Jon C. Ogg | Jun 7, 2016 at 8:50 AM EDT

Top Analyst Upgrades and Downgrades: First Data, GE, Sarepta, Western Digital, Walgreens, Zillow and More

The top analyst upgrades, downgrades and initiations seen on Tuesday morning include First Data, General Electric, Sarepta Therapeutics, Western Digital,…

Chris Lange | Jun 5, 2016 at 10:05 AM EDT

5 Companies That Destroyed Shareholders Last Week

Sarepta Therapeutics and Globalstar are among the companies that punished shareholder the most this past week.

Chris Lange | May 25, 2016 at 11:55 AM EDT

Why Sarepta’s PDUFA Delay Is a Good Thing

Sarepta Therapeutics Inc. (NASDAQ: SRPT) shares saw a handy gain on Wednesday following an analyst upgrade from Janney Montgomery Scott.

Chris Lange | May 8, 2016 at 9:45 AM EDT

4 Major FDA Decisions Expected by June

Several big FDA decisions should be coming up in the June quarter for the likes of AstraZeneca and Sarepta Therapeutics.

Chris Lange | May 1, 2016 at 10:55 AM EDT

5 Companies That Destroyed Shareholders Last Week

Apple, Twitter and other companies punished shareholders last week, and analysts expect more earnings disappointments going forward.

Jon C. Ogg | Apr 29, 2016 at 9:10 AM EDT

Top Analyst Upgrades and Downgrades: Amazon, Ford, Gilead, Level 3, Sarepta, Western Digital, Whiting Petroleum and More

The top analyst upgrades, downgrades and initiations seen on Friday morning include Amazon, Ford, Gilead, Level 3, Sarepta, Western Digital…

Paul Ausick | Apr 26, 2016 at 4:04 PM EDT

The 52-Week Low Club for Tuesday

April 26, 2016: Here are four stocks trading with relatively heavy volume among 14 equities making new 52-week lows in…

Jon C. Ogg | Apr 26, 2016 at 8:55 AM EDT

Top Analyst Upgrades and Downgrades: Broadcom, Caterpillar, Sirius XM, Newmont, Palo Alto, Perrigo, Sarepta, Xerox and More

The top analyst upgrades, downgrades and initiations seen on Tuesday morning include Broadcom, Caterpillar, Sirius XM, Newmont, Palo Alto, Perrigo,…

1 … 4 5 6 7 8 … 10

Sarepta Therapeutics : SRPT

All Sarepta Therapeutics Articles

Top Analyst Upgrades and Downgrades: American Electric Power, Broadcom, Ford, GM, JD.com, Sarepta, Valeant Pharmaceuticals and More

Sarepta Scores Big on Highly Contested FDA Approval

Top Analyst Upgrades and Downgrades: Apple, AT&T, Autodesk, Bluebird Bio, Monsanto, Sarepta and More

Why This FDA Departure Is Huge for Sarepta

4 Red-Hot Biotech Stocks With Over 100% Upside Potential

3 Biotechs That Just Announced Successful Phase 2 Trials

Why Analysts Are Still All Over the Place on Sarepta After FDA News

Top Analyst Upgrades and Downgrades: First Data, GE, Sarepta, Western Digital, Walgreens, Zillow and More

5 Companies That Destroyed Shareholders Last Week

Why Sarepta’s PDUFA Delay Is a Good Thing

4 Major FDA Decisions Expected by June

5 Companies That Destroyed Shareholders Last Week

Top Analyst Upgrades and Downgrades: Amazon, Ford, Gilead, Level 3, Sarepta, Western Digital, Whiting Petroleum and More

The 52-Week Low Club for Tuesday

Top Analyst Upgrades and Downgrades: Broadcom, Caterpillar, Sirius XM, Newmont, Palo Alto, Perrigo, Sarepta, Xerox and More

UFO ETF Faces a Critical Test: Can Pre-Profit Space Stocks Deliver on $1.85B Backlog

Concentration Risk High as Top Two Stocks Steer U.S. Communication Services ETF Performance

Amazon and Tesla Drive One-Third of FDIS as U.S. Spending Surges Despite Recession-Level Sentiment

Fed’s Rate Freeze Could Sting for Social Security Recipients

'Convert $100,000 a Year to Get Them to the Top of the 22%': The Roth Plan for a Couple With $2.3M in 401(k)s

UFO ETF Faces a Critical Test: Can Pre-Profit Space Stocks Deliver on $1.85B Backlog

Concentration Risk High as Top Two Stocks Steer U.S. Communication Services ETF Performance

Sarepta Therapeutics : SRPT

All Sarepta Therapeutics Articles

Top Analyst Upgrades and Downgrades: American Electric Power, Broadcom, Ford, GM, JD.com, Sarepta, Valeant Pharmaceuticals and More

Sarepta Scores Big on Highly Contested FDA Approval

Top Analyst Upgrades and Downgrades: Apple, AT&T, Autodesk, Bluebird Bio, Monsanto, Sarepta and More

Why This FDA Departure Is Huge for Sarepta

4 Red-Hot Biotech Stocks With Over 100% Upside Potential

3 Biotechs That Just Announced Successful Phase 2 Trials

Why Analysts Are Still All Over the Place on Sarepta After FDA News

Top Analyst Upgrades and Downgrades: First Data, GE, Sarepta, Western Digital, Walgreens, Zillow and More

5 Companies That Destroyed Shareholders Last Week

Why Sarepta’s PDUFA Delay Is a Good Thing

4 Major FDA Decisions Expected by June

5 Companies That Destroyed Shareholders Last Week

Top Analyst Upgrades and Downgrades: Amazon, Ford, Gilead, Level 3, Sarepta, Western Digital, Whiting Petroleum and More

The 52-Week Low Club for Tuesday

Top Analyst Upgrades and Downgrades: Broadcom, Caterpillar, Sirius XM, Newmont, Palo Alto, Perrigo, Sarepta, Xerox and More

UFO ETF Faces a Critical Test: Can Pre-Profit Space Stocks Deliver on $1.85B Backlog

Concentration Risk High as Top Two Stocks Steer U.S. Communication Services ETF Performance

Amazon and Tesla Drive One-Third of FDIS as U.S. Spending Surges Despite Recession-Level Sentiment

Featured Reads

Fed’s Rate Freeze Could Sting for Social Security Recipients

'Convert $100,000 a Year to Get Them to the Top of the 22%': The Roth Plan for a Couple With $2.3M in 401(k)s